

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-10. (Cancelled).

11. (Currently Amended) An isolated polypeptide of any one of (a) to ~~(e)~~ (b) described below:

(a) a polypeptide comprising ~~the~~ an amino acid sequence of any one of SEQ ID NOs: 1 and 3 to 12 ~~1 to 12~~; and

(b) a polypeptide comprising a peptide region cyclized by a disulfide bond formed between cysteine residues on both ends of the polypeptide of (a); ~~and~~

~~(c) a polypeptide having brain-localizing activity, and comprising an amino acid sequence with one or several amino acid additions, deletions, or substitutions in the amino acid sequence of any one of SEQ ID NOs: 1 to 12.~~

12. (Currently Amended) The polypeptide of ~~any one of claims 1 to 11~~ claim 11, wherein the length of the polypeptide is 9 amino acids or less.

13.-14. (Cancelled).

15. (Currently Amended) A pharmaceutical agent for conferring brain-localizing activity to an arbitrary molecule, wherein the agent comprises the polypeptide of ~~any one of claims 1 to 12~~ claim 11.

16. (Original) The pharmaceutical agent of claim 15, wherein the arbitrary molecule is an arbitrary polypeptide.

17. (Currently Amended) A molecule having brain-localizing activity, wherein the molecule comprises the polypeptide of ~~any one of claims 1 to 12~~ claim 11.

18. (Original) The molecule of claim 17, wherein the molecule is a phage particle or a coat protein of a phage particle.

19. (Currently Amended) The molecule of claim 17, wherein the molecule is a fusion protein formed with the polypeptide of ~~any one of claims 1 to 12~~ claim 11.

20. (Currently Amended) A carrier for delivery to the brain, wherein the carrier comprises the polypeptide of ~~any one of claims 1 to 12~~ claim 11.

21. (Currently Amended) A carrier for delivery to the brain, wherein the carrier comprises a structure in which the polypeptide of ~~any one of claims 1 to 12~~ claim 11 is bound to a micelle, liposome, or microcapsule.

22. (Original) A therapeutic agent for brain disease, wherein the agent comprises a structure in which a drug is supported by the carrier of claim 20 or 21.

23. (Currently Amended) A method for producing a molecule having brain-localizing activity, wherein the method comprises binding ~~the polypeptide of any one of claims 1 to 12~~ to an arbitrary molecule a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 1 to 12.

24. (Cancelled).

25. (Currently Amended) A method for translocating an arbitrary molecule into the brain of ~~a non-human~~ an animal, wherein the method comprises the steps of:

(a) producing a molecule having brain-localizing activity, wherein the molecule comprises a structure in which an arbitrary molecule is bound to a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 1 to 12 ~~the polypeptide of any one of claims 1 to 12~~; and

(b) administering the molecule into the body of the ~~non-human~~ animal.

26. (Withdrawn - Currently Amended) A method of screening for a molecule having binding activity to a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 1 to 12 ~~the polypeptide of any one of claims 1 to 12~~, wherein the method comprises the steps of:

(a) contacting ~~the polypeptide of any one of claims 1 to 12~~ with a test molecule a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 1 to 12;

(b) detecting binding activity between the polypeptide and the test molecule; and

(c) selecting a molecule that binds to the polypeptide.

27. (Withdrawn) A method of screening for a polypeptide having brain-localizing activity, wherein the method comprises the steps of:

(a) preparing a phage particle displaying a test polypeptide on its phage coat protein;

(b) administering the phage particle to a non-human animal;

(c) collecting a phage particle from a brain tissue of the non-human animal; and

(d) selecting a test polypeptide displayed on the phage particle collected in step (c) as a polypeptide having brain-localizing activity.

28. (Withdrawn – Currently Amended) The method of claim 27, wherein the test polypeptide comprises ~~the~~ an amino acid motif sequence of any one of SEQ ID NOs: 1 to 12 ~~any one of claims 5, 7, and 8~~.

29. (Withdrawn) The method of claim 27, wherein the phage is M13 phage or T7 phage.

30. (Withdrawn – Currently Amended) The method of claim 27, wherein the method further comprises selecting a phage particle that binds to a ~~cerebrovascular~~ cerebrovascular endothelial cell subsequent to step (a).